Cases & Deals

AbbVie successfully defends patents related to HUMIRA® against IPR petitions filed by Amgen

Clients AbbVie Inc.

Jones Day served as co-counsel in the successful defense of AbbVie Inc. in two IPRs brought by Amgen in connection with U.S. Patent Nos. 8,916,157 and 8,916,158 related to AbbVie's blockbuster antibody therapeutic, HUMIRA®. Following filing of the Patent Owner's Preliminary Responses by AbbVie, the PTAB denied institution of both IPRs.

Amgen Inc. v. AbbVie Biotechnology Ltd. et al., IPR2015-01514, -01517 (PTAB)

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.